

# Coronary Stents: Market Research Report

<https://marketpublishers.com/r/CA83E20B8A8EN.html>

Date: October 2011

Pages: 396

Price: US\$ 4,500.00 (Single User License)

ID: CA83E20B8A8EN

## Abstracts

This report analyzes the worldwide markets for Coronary Stents in US\$ Million and Thousand Units by the following Product Segments: Bare Metal Stents, and Drug Eluting Stents.

The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

A six-year historic analysis is also provided for these markets.

The report profiles 53 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### **1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Bare Metal Stents

Drug Eluting Stents

### **2. GLOBAL MARKET OVERVIEW**

Growth Revives as Drug Eluting Stents Bounce Back

What's Next on Cards in Coronary Stent Market?

Market Snapshots

Current and Future Analysis

Drug Eluting Stents Steal the Show

Star Player J&J to Quit DES Business in an Expensive Market Withdrawal

### **3. MARKET TRENDS AND ISSUES**

Drug Eluting Stent System – Safety Concerns

Declining Prices – A Major Concern

Restenosis - the Real Growth Driver

Small Vessels – A Major Cause of Restenosis

Aging Population Propels Coronary Stent Market

Next Generation Stents – A Boon for Treating Coronary Diseases

Direct Stenting Systems Spur Growth

Drug Choice Impacts Market Entry

Threats to Coronary Stents – Alternative Therapies/Devices

Cell Transplantation – A Major Threat to Coronary Stents

Coronary Stents Market Challenged by Drug Therapy

### **4. COMPETITIVE ANALYSIS**

Coronary Stents – Leading Players

**Table 1.** Leading Players in the Global Coronary Stents Market (2010 & 2012) – Percentage Breakdown of Market Share by Company - Boston Scientific, Abbott (Guidant), Johnson & Johnson, Medtronic, and Others (includes corresponding Graph/Chart)

Bare Metal Stents – Leading Players

**Table 2.** Leading Players in the Global Bare Metal Stents Market (2010) – Percentage Breakdown of Share for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart)

Drug-Eluting Stents – Leading Players

**Table 3.** Global Drug Eluting Stents Market (2010): Percentage Breakdown of Share by Company - Boston Scientific, Abbott Labs, Johnson and Johnson, Medtronic, Others (includes corresponding Graph/Chart)

Major DES Types in the Market and Leading Manufacturers  
Comparative Analysis of the Leading Players

## **5. CORONARY DISEASE - A PERSPECTIVE**

Factors Responsible for Coronary Diseases

Controllable Risk Factors

High Blood Cholesterol

Sedentary Life Style and Habits

Smoking Habits

High Blood Pressure

Uncontrollable Risk Factors

Age

Heredity

Gender

Causative Risk Factors

Stress and Anger

Obesity

Diabetes

Symptoms of Coronary Artery Disease

Diagnosis

Treatment

Drug Supported Treatments

Invasive Treatments

Bypass Surgery

Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty)

Natural Therapy

Coronary Angioplasty Suitable for Acute Myocardial Infarction

Advancements in Coronary Disease Treatment Modalities

University of Virginia's Microbe Solution for Post Surgical Complications

Radiation for Re-clogged Arteries Show Promise

Radioactive Coronary Stents Promise Bright Future

## **6. CORONARY STENTS - PRODUCT OVERVIEW**

Introduction

Evolution of Coronary Stents

Applications of Coronary Stents

Stent Deployment

Key Stent Delivery Platforms by Select Company

Coronary Stent Designs

Key Factors Determining Coronary Stent Performance

Delivery Convenience

Efficient Scaffolding

Radiopacity (Visibility)

Optimum Flexibility

Shape Conformability

Material for Coronary Stent

Risk Associated with Stenting

Improper Stent Implantation Likely Cause for In-Stent Restenosis

Precautions

Direct Coronary Stenting – Creating an Enliven

Limitations

Regulatory Approvals Wooing Stent Market

A Peek into Regulatory Approvals for Coronary Stents

## **7. PRODUCT SEGMENTS**

Bare Metal Stents  
Major Bare Metal Stents by Company  
Drug-Eluting Stents  
DE Stents Overshadow Intravascular Brachytherapy Interventions  
Major Drug-Eluting Stents by Company  
Drugs for Coating DESs  
Cytotoxic or Cytostatic Drug – the Debate Continues  
Dosing and Deliverability Crucial for DES  
Polymer Coatings for Effective Dosing and Deliverability  
Drugs Used for DES by Major Competitors in the Stent Market  
Leading Coronary Stent Brands  
Cypher  
Structure and Delivery Mechanism  
Taxus  
Structure and Delivery Mechanism

## **8. RESEARCH AND DEVELOPMENT**

Extensive R&D Underway in Global Drug-Eluting Stents Market  
At the Labs  
Other Products Under Trials – A Recent Past Perspective  
OMT Developing R-stent  
Reva Developing Stainless Steel Bare-Metal Stent  
D&P Corp Developing Bovine Pericardium- Covered Stent  
Advanced Bio Synthesizing Porous Drug-Eluting Stents  
Lombard Medical Developing PEP Coatings  
Shiga Develops Biodegradable Drug-Eluting Stent

## **9. PRODUCT INNOVATIONS/INTRODUCTIONS**

Boston Scientific Launches ION™ Platinum Chromium Stent System  
Terumo Introduces Nobori Drug-Eluting Coronary Stent  
Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™ Stent Systems  
Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent System  
Boston Scientific Launches Taxus Element Stent System in European Union  
Cordis Introduces PRESILLION™ PLUS Stent System in Europe  
Medtronic Launches Resolute Integrity Stent System  
InspireMD Unveils MGuard Prime  
Boston Scientific Introduces Taxus Eluting Stent System

Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting Stent System in Japan  
Alvimedica Launches Coracto Drug-Eluting Stent in Europe  
Abbott Labs to Launch XIENCE V in China  
Medtronic Launches Driver Sprint RX Coronary STENT System  
Existent Introduces Premier Coronary Stent System  
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents  
NanoInterventions Launches Mouse Stent Model  
InspireMD - MGuard™ Coronary Stent Launched in Italy  
CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin  
Polyzene®-F  
Angiotech Launches Cook Medical's Drug Eluting Zilver® PTX™ Stent in New Zealand

## **10. RECENT INDUSTRY ACTIVITY**

Boston Scientific Receives FDA Approval for Novel Paclitaxel-Eluting Coronary Stent  
Boston Scientific Receives Approval for Distribution of PROMUS® Everolimus-Eluting Stent  
Cordis Discontinues Production of NEVO™ Sirolimus- Eluting Coronary Stents  
Boston Scientific Receives FDA Approval for ION Stent  
Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid Stent System Application  
Boston Scientific Receives CE Mark Approval for OMEGA™ Platinum Chromium Stent System  
Stentys Launches Stents across Additional Countries in Europe  
Opto Circuits Acquires N. S. Remedies  
Biosensors International Group Takes Over Assets of Devax  
Cordis Signs Distribution Agreement with Ostial Solutions  
Medtronic Obtains FDA Approval for Integrity Coronary Stent System  
Boston Scientific Receives Approval from Japanese MHLW for PROMUS® Coronary Stent  
InspireMD Selects Kirloskar Technologies for Distributing Coronary Stent Systems  
Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary Stent System  
Boston Scientific Receives TGS Approval from Australia  
Svelte Medical Systems Commences Clinical Trial of SOAW Delivery System  
Abbott Receives Japan's MHLW Approval for Xience V  
Opto Circuits Receives Mark Approval from Communité European  
Abbott Receives Health Canada Approval for XIENCE V® Stent System  
Medtronic Secures Japan's MHLW Approval for Endeavor® Drug Eluting Stent  
Boston Scientific Takes Over Labcoat

Micell and Maxcor Sign Strategic Agreement  
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-Eluting Coronary Stent  
Boston Scientific Obtains CE Mark Approval for Promus Element Everolimus-Eluting Coronary Stent System  
Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE Mark for Treatment in Diabetic Patients  
Atrium Medical Obtains CE Mark for Cinatra™  
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting Stent for Use in Treatment of ACS  
CorNova® Obtains CE mark approval for Valecor Platinum Coronary Stent System  
Cook Medical Receives CE Mark Approval and Launches Zilver® PTX® Drug-Eluting Peripheral Stent  
Disa Receives CE Approval for Coronary Stent  
Datascope Acquires Peripheral Stent Business of Sorin Group  
Boston Scientific Receives FDA approval for TAXUS® Liberte® Drug-Eluting STENT  
Abbott Labs Receives FDA Approval for Xience V  
Bard to Purchase Assets of LifeStent Product Portfolio  
Medtronic Receives the US FDA Approval to Use Endeavor® Stent  
Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In Canada  
Boston Scientific to Market TAXUS® Liberte® Stent System in Canada  
Abbott Applies for Approval of XIENCE™ V in Japan  
Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent System  
Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary Stent  
Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark approval  
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European Entry  
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval  
CV Therapeutics Offers its Stent Coating Technology to Medlogics Device Corporation  
Abbott’s 2. 25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of Approval  
Biosensors Receives CE Mark Approval for BioMatrix® Stent System  
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark Approval

## **11. FOCUS ON SELECT GLOBAL PLAYERS**

Angiotech Pharmaceuticals (Canada)  
Abbott Vascular (USA)  
Biosensors International (USA)



Boston Scientific Corp. (USA)  
Cordis Corporation (JNJ) - (USA)  
Medtronic, Inc. (USA)  
Medtronic Cardiovascular, Inc. (USA)  
OrbusNeich (Hong Kong)  
Terumo Europe N. V. (Belgium)

## 12. GLOBAL MARKET PERSPECTIVE

**Table 4.** World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 5.** World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 6.** World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 7.** World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 8.** World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 9.** World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)



**Table 10.** World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 11.** World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 12.** World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 13.** World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 14.** World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 15.** World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 16.** World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 17.** World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 18.** World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sale sin US\$ Million for Years 2003 through

2008(includes corresponding Graph/Chart)

**Table 19.** World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 20.** World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 21.** World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 22.** World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 23.** World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 24.** World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 25.** World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 26.** World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding

Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 27.** World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

### 13. THE UNITED STATES

#### A. Market Analysis

Largest Market Worldwide

Coronary Artery Disease - A US Perspective

Baby Boomers Boost Coronary Stent Market

Revival in the DES Market

Reimbursement System

National Average Medicare Payment For DRGS

Competitive Scenario

Leading Players

Coronary Stents – Boston Scientific and JNJ Battle for Dominance

**Table 28.** Leading Players in the US Coronary Stents Market (2010) – Percentage Breakdown of Share for Boston Scientific, Abbott and Johnson & Johnson (includes corresponding Graph/Chart)

Drug Eluting Stents – Competition in the Brewing

**Table 29.** Leading Players in the US Drug-Eluting Stents Market (2010) – Percentage Breakdown of share for Boston Scientific, Abbott Labs, J&J-Cordis and Medtronic (includes corresponding Graph/Chart)

Regulatory Environment

#### B. Market Analytics

**Table 30.** US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with

Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 31.** US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 32.** US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 33.** US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 34.** US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 35.** US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 14. JAPAN

### A. Market Analysis

Prospects Weighed down by Regulatory Entanglements

Japanese Coronary Stents Command Higher Prices

**Table 36.** Coronary Stent Pricing (2008): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart)

### Competitive Landscape

**Table 37.** Leading Players in the Japanese Coronary Stent Market ( 2010) – Percentage Breakdown of Share for Johnson & Johnson, Medtronic, Boston Scientific,

and Others (includes corresponding Graph/Chart)

**Table 38.** Leading Players in the Japanese Bare Metal Stent Market (2010) – Percentage Breakdown by of Share for Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart)

**Table 39.** Leading Players in Japanese Drug-Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson and Boston Scientific (includes corresponding Graph/Chart)

## B. Market Analytics

**Table 40.** Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 41.** Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 42.** Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 43.** Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 44.** Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 45.** Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 15. EUROPE

### A. Market Analysis

Cardiovascular Disease in Europe – A Perspective

Growth Bar Too Low

Two-Speed Europe

Stent Market's Merger Mania

Dampeners to Rapid Adoption of DES in Europe

Competitive Scenario

**Table 46.** Leading Players in the European Drug- Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart)

### B. Market Analytics

**Table 47.** European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 48.** European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 49.** European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 50.** European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 51.** European 15-Year Perspective for Coronary Stents by Geographic Region –



Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 52.** European 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 53.** European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 54.** European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 55.** European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 56.** European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 57.** European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 58.** European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **15A. FRANCE**

### Market Analysis



**Table 59.** French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 60.** French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 61.** French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 62.** French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 63.** French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 64.** French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **15B. GERMANY**

### Market Analysis

**Table 65.** German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 66.** German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently

Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 67.** German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 68.** German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 69.** German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 70.** German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **15C. ITALY**

### Market Analysis

**Table 71.** Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 72.** Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 73.** Italian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 74.** Italian Historic Review for Coronary Stents by Product Segment – Bare Metal

and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 75.** Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 76.** Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **15D. THE UNITED KINGDOM**

### Market Analysis

**Table 77.** UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 78.** UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 79.** UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 80.** UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 81.** UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 82.** UK 15-Year Perspective for Coronary Stents by Product Segment -

Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 15E. SPAIN

Market Analysis

**Table 83.** Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 84.** Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 85.** Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 86.** Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 87.** Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 88.** Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 15F. RUSSIA

Market Analysis

**Table 89.** Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 90.** Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 91.** Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 92.** Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 93.** Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 94.** Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **15G. REST OF EUROPE**

### Market Analysis

**Table 95.** Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 96.** Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes

corresponding Graph/Chart)

**Table 97.** Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 98.** Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 99.** Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 100.** Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 16. ASIA-PACIFIC

### A. Market Analysis

China – Healthcare Reforms to Propel DES Market

**Table 101.** Coronary Stent Market in China (2010): Percentage Breakdown of Market Share by Company- Shanghai Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic and Others (includes corresponding Graph/Chart)

Coronary Stent Market in a Bubble Zone Now

Regional Players and their DES Development Efforts

Cost Focus Helps Stent Makers Win the Market Stunt

### B. Market Analytics

**Table 102.** Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)



**Table 103.** Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 104.** Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008(includes corresponding Graph/Chart)

**Table 105.** Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008(includes corresponding Graph/Chart)

**Table 106.** Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 107.** Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **17. REST OF WORLD**

### A. Market Analysis

Brazil – Low Penetration of DES

South Africa – Leading Players

**Table 108.** Leading Players in South African Coronary Stent Market (2010) – Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott and Others (includes corresponding Graph/Chart)

### B. Market Analytics

**Table 109.** Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)



**Table 110.** Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 111.** Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US\$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 112.** Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 113.** Rest of World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 114.** Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **COMPETITIVE LANDSCAPE**

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 62)

Region/Country Players

The United States 34

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

Africa

## I would like to order

Product name: Coronary Stents: Market Research Report

Product link: <https://marketpublishers.com/r/CA83E20B8A8EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA83E20B8A8EN.html>